Introduction {#sec1-1}
============

Ischemic stroke is one of the leading causes of death and long-term disability worldwide. At present, reperfusion with either thrombolysis with recombinant tissue plasminogen activator or mechanical thrombectomy is the only effective treatment for acute ischemic stroke. However, its clinical efficacy is limited by the fact that it must be applied within a narrow time window after stroke and it increases risk of bleeding (Hafeez et al., 2007; Zhang et al., 2011; Baltsavias et al., 2015). As a result, continued efforts have been made to investigate various potential neuroprotective strategies to mitigate or eliminate ischemic injury, but no alternatives have yet been validated in the clinic.

Ischemia causes rapid loss of energy stores and generalized depolarization; this induces glutamate release and a large increase of cytosolic Ca^2+^, which triggers apoptosis (White et al., 2000). Thus, an obvious strategy to protect against ischemic injury would be to inhibit N-methyl-D-aspartic acid receptor (NMDAR)-mediated Ca^2+^ influx, but generalized and lasting NMDAR inhibition results in side effects that strongly restrain its clinical application. It has been suggested that chemical compounds that transiently and reversibly block NMDARs have the greatest benefit potential to mitigate excitotoxicity-evoked brain damage (Chen et al., 2017).

Accumulating evidence suggests that imidazoline I~2~ receptor (I~2~R) ligands have various biological functions, including effective analgesia for inflammatory pain and neuroprotection (Bousquet et al., 1998; Zhu et al., 2015). We have shown *in vitro* and *in vivo* that 2-(2-benzofu-ranyl)-2-imidazoline (2-BFI) is the most effective I~2~R ligand for protecting neurons from ischemic damage and that it works by directly modulating NMDAR-mediated Ca^2+^ influx into neurons (Han et al., 2009, 2012, 2013; Thorn et al., 2016). 2-BFI triggers reversible blockade of Ca^2+^ influx with a relatively fast off-rate, similarly to memantine (Han et al., 2013). This suggests that 2-BFI may trigger fewer adverse effects in cognition analogously to memantine, which only works when agonist levels are pathologically high. Indeed, memantine has been clinically approved as a treatment for dementia and it is being tested in clinical trials as a treatment for vascular dementia and stroke (Orgogozo et al., 2002; Matsunaga et al., 2015). It is in great need to clarify whether 2-BFI offers the same advantages as memantine.

Prior to such work, however, it is important to determine whether 2-BFI can exert clinically useful neuroprotective effects when given up to several hours after injury. If not, the clinical usefulness of 2-BFI may be severely limited, since it is usually impossible to administer stroke medications immediately after injury. Previous studies of 2-BFI have assessed its efficacy only after immediate administration. Thus, in the present study, we examined whether 2-BFI administered with various delays after stroke onset can protect against ischemic injury in rats. Our results will help establish the potential of 2-BFI for clinical translation and begin to elucidate the drug\'s neuroprotective mechanism of action.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

A total of 90 adult clean male Sprague-Dawley rats aged 3--4 months and weighing 250--270 g were obtained from Wenzhou Medical College, Wenzhou, China (SYXK (Zhe) 2007-0005). For 1 week prior to surgery, rats were housed under a 12-hour light/dark cycle and allowed free access to food and water. All experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication 80-23) and the Animal Use Guidelines of Wenzhou Medical University (wydw2016-0200). Every effort was made to minimize the number of animals used and their suffering. The rats were randomly assigned to eight groups: sham, 0-hour, 1-hour, 3-hour, 5-hour, 7-hour, 9-hour, and middle cerebral artery occlusion (MCAO) without treatment.

MCAO-induced ischemia and 2-BFI intervention {#sec2-2}
--------------------------------------------

Rats were temporarily anesthetized using 10% chloral hydrate (Sheng Yang Ze Run Company, Beijing, China). The right middle cerebral artery was then occluded for 120 minutes using an intraluminal filament (Longa et al., 1989), with minor modifications. During and after surgery, animal body temperature was monitored using a rectal probe and maintained at 37°C using a heating pad and lamp. Sham rats (*n* = 6) underwent surgery but not occlusion. The MCAO group (*n* = 12) underwent occlusion and received the same amount of saline. Treated rats received a bolus injection of 2-BFI (3 mg/kg; Tocris Bioscience, Bristol, UK) through the tail vein at 0, 1, 3, 5, 7, or 9 hours after reperfusion (*n* = 12 each). Our previous study has shown that this dose of 2-BFI can efficiently protect against transient ischemia when administered immediately after ischemia (Zhao et al., 2008).

Assessment of neurological deficit {#sec2-3}
----------------------------------

Thirty minutes before MCAO and 22 hours after reperfusion, beam balance performance was measured, as described previously (Schäbitz et al., 2004). At least three measurements were taken for each animal at each time point, and the mean and standard error were calculated. At 22 hours after occlusion, neurological deficit was measured using an expanded six-point scale (Longa et al., 1989). The balance and Longa scores were added to obtain one overall score for each rat. All assessments were performed by investigators blinded to the control or treatment. Average scores were used for statistical analysis.

Measurement of infarct volume {#sec2-4}
-----------------------------

At 22 hours after the reperfusion, rats were sacrificed using 10% chloral hydrate. Coronal brain sections (2 mm thick) were prepared, and stained at 37°C for 20 minutes with a 4% solution of 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, St. Louis, MO, USA). The sections were examined using computer-assisted Image-Pro Plus analysis (Media Cybernetics Company, Rockville, MD, USA) and standard techniques to determine infarct surface area. To minimize error introduced by edema, infarct volume in the ischemic region was normalized to the volume of the non-ischemic region and expressed as a percentage of contralateral brain volume.

Brain histopathology assay {#sec2-5}
--------------------------

At 22 hours after occlusion, rats were anesthetized with 10% chloral hydrate and perfused transcardially with saline, followed by 4% formaldehyde in phosphate-buffered saline (PBS). Brains were removed, post-fixed in 4% formaldehyde (pH 7.4) for 18 hours and cryoprotected in 30% sucrose for 36 hours at 4°C. Coronal sections (10 μm thick) were cut using a cryostat (Leica Microsystems, Wetzlar, Germany), mounted on superfrost slides (Fisher Scientific, Toronto, Canada), and stored at −80°C. Slides were stained with hematoxylin and eosin and examined under a light microscope (Leica Microsystems).

Electron microscopy {#sec2-6}
-------------------

Brain tissue was fixed for 2 hours in 3% glutaraldehyde buffered in sodium cacodylate (pH 7.4) and post-fixed in 1% osmium tetroxide in cacodylate buffer, dehydrated in graded ethanol solutions, and embedded in Araldite. Thin sections were cut on a Reichert-Jung Ultracut ultramicrotome, mounted on 300-mesh copper grids, and stained in saturated uranyl acetate in alcohol for 10 minutes and lead citrate for 8 minutes. Sections were examined using a transmission electron microscope (H-600A-2; Hitachi, Tokyo, Japan).

TdT-mediated dUTP nick end-labeling (TUNEL) assay {#sec2-7}
-------------------------------------------------

Fixed frozen brain sections were permeabilized in 0.1% Triton X-100 for 15 minutes. After washing in PBS, sections were incubated at 37°C for 1 hour in a 50-μL solution containing 1× TdT buffer (catalog No. 16314015; Life Technologies, Rockville, MD, USA), 11.1 μM biotin-dUTP (catalog No. B32766; Life Technologies), and 20 U of TdT (Life Technologies). The sections were blocked with 2% bovine serum albumin in PBS, incubated in streptavidin-horseradish peroxidase (1:4000; Haoran Biotech Co., Shanghai, China) for 30 minutes, and stained with 3,3′-diaminobenzidine (1:9; Beijing Zhongshan Jinqiao Co., Beijing, China) for 15 minutes. The coverslips were then mounted using mounting medium and examined under an optical microscope (Leica, Oskar-Barnack-Straße, Germany).

Immunohistochemistry {#sec2-8}
--------------------

Apoptosis-related proteins, Bcl-2 and BAX, were mainly expressed in the cytoplasm of neurons and were detected using immunohistochemistry (Yenari and Hemmen, 2010). Immunohistochemistry was performed as previously described (Han et al., 2012). Sections were brought to room temperature, washed with PBS, and incubated in 3% H~2~O~2~ in PBS to quench endogenous peroxidase. The sections were blocked for 1 hour with 5% bovine serum albumin in PBS, and incubated overnight at 4°C with rabbit anti-rat Bcl-2 monoclonal antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, TX, USA) or rabbit anti-rat BAX monoclonal antibody (1:100; Santa Cruz Biotechnology). Finally, sections were incubated with secondary antibody (goat anti-rabbit IgG-B 1:500; Santa Cruz Biotechnology) for 20 minutes at 37°C, and visualized with diaminobenzidine (Santa Cruz Biotechnology). The samples were observed under an optical microscope (Leica Microsystems).

Statistical analysis {#sec2-9}
--------------------

Results are expressed as the mean ± SE. Statistical analyses were performed using SPSS 17.0 (IBM SPSS, Shanghai, China). Differences between treatment and MCAO groups were assessed for significance using paired *t*-tests. A value of *P* \< 0.05 was considered as statistically significant.

Results {#sec1-3}
=======

2-BFI alleviates the neurological impairment in cerebral ischemia/reperfusion rats {#sec2-10}
----------------------------------------------------------------------------------

After MCAO, rats showed signs of neurological impairment, such as retracting the left forepaw, circling to the left, and/or falling when walking, while the sham group showed no sign of neurological deficits. Treatment with 2-BFI improved neurological outcomes, and the extent of improvement depended on when the drug was administered; the earlier 2-BFI was given after reperfusion, the better the behavioral outcome (**[Figure 1](#F1){ref-type="fig"}**). At 22 hours after MCAO, neurological deficit scores were significantly lower in rats treated with 2-BFI within 5 hours after reperfusion than those in MCAO rats (all *P* \< 0.05; **[Figure 1A](#F1){ref-type="fig"}**).

![Time window for 2-BFI therapeutic efficacy against cerebral ischemia/reperfusion in rat models.\
Rats were subjected to 2-hour MCAO followed by reperfusion. At 0, 1, 3, 5, 7, or 9 hours after reperfusion, 2-BFI (3 mg/kg) was injected intravenously and rats were killed at 22 hours of reperfusion. (A) Neurological deficits were less apparent in rats treated with 2-BFI (*n* = 12) than rats in the MCAO group. Neurological deficit was measured using an expanded 6-point scale. (B) Percent reduction in infarct volume was significantly greater in rats treated with 2-BFI (*n* = 12). (C) 2,3,5-Triphenyl-2H-tetrazolium chloride staining of coronal brain slices indicated the reduction in brain infarction (whitish area on the left hemisphere). Data are expressed as the mean ± SE (paired *t*-test). \**P* \< 0.05, \*\**P* \< 0.01, *vs*. MCAO group. 2-BFI: 2-(2-Benzofu-ranyl)-2-imidazoline; MCAO: middle cerebral artery occlusion; h: hour(s).](NRR-13-2111-g002){#F1}

However, according to behavioral measures, 2-BFI administered at 7 and 9 hours after reperfusion had no protective effect (**[Figure 1A](#F1){ref-type="fig"}**). Brain infarct volume compared with the contralateral side was significantly smaller in rats treated with 2-BFI than that of in the MCAO group (**[Figure 2](#F2){ref-type="fig"}**). The protective effect of 2-BFI was greater when it was administered earlier after injury (**Figure [1B](#F1){ref-type="fig"}, [C](#F1){ref-type="fig"}**). The infarct volumes were reduced by 2-BFI after reperfusion by 77.1%, 67.8%, 65.4%, 59.2%, 38.2%, and 12.4% at 0, 1, 3, 5, 7, and 9 hours, respectively, compared with the MCAO group (all *P* \< 0.05; **[Figure 1B](#F1){ref-type="fig"}**).

![Histology and ultrastructural analysis of mitigation of neuronal injury in cerebral ischemia/reperfusion rats by 2-BFI.\
Rats were subjected to 2-hour MCAO followed by reperfusion. At 0, 1, 3, 5, 7, or 9 hours after reperfusion, 2-BFI (3 mg/kg) was injected intravenously and rats were killed at 22 hours of reperfusion. (A) Brains were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. MCAO led to pyknosis, homogeneous cytoplasm, and increased numbers of vacuoles. 2-BFI treatment mitigated these negative effects. Arrowheads indicate vacuoles. (B) Neurons from the peri-infarct cortex of the ipsilateral side were examined using electron microscopy. The double nuclear membrane is clearly visible in the boxed area in sham rats, and there is no condensed chromatin next to the membrane. Injury to the neurons causes thickened membrane and condensed chromatin along membrane. Neurons from the brains exposed to MCAO show a thickened nuclear membrane and condensed chromatin (white arrowheads). In rats given 2-BFI within 9 hours after injury, the membrane was less thick and there were fewer chromatin deposits near the nuclear membrane. 2-BFI: 2-(2-Benzofu-ranyl)-2-imidazoline; MCAO: middle cerebral artery occlusion; h: hour(s). Scale bars: 10 μm.](NRR-13-2111-g003){#F2}

2-BFI treatment reduces brain cell death in cerebral ischemia/reperfusion rats {#sec2-11}
------------------------------------------------------------------------------

Hematoxylin-eosin staining was used to determine the severity of neuronal injury in the ischemic penumbra after ischemia/reperfusion (Han et al., 2012). In sham-operated rats, cortical neurons had an orderly arrangement, distinct outlines, and a compact structure (**[Figure 2A](#F2){ref-type="fig"}**). In contrast, the ischemic penumbra of MCAO rats showed numerous, irregularly arranged eosinophilic neurons with homogeneous cytoplasm that lacked subcellular structures and/or that showed a triangulated karyopyknosis. 2-BFI treatment at all time points appeared to alleviate these effects, with the greatest protection observed when the drug was administered within 5 hours after reperfusion (**[Figure 2A](#F2){ref-type="fig"}**).

Electron microscopy revealed that the cortical neurons of sham-operated rats had an orderly arrangement, clear outlines, and a compact structure. The electronic density of the nucleus and cytoplasm was even, nuclear membranes were clear, and chromatins were well distributed. In the MCAO and 2-BFI treatment groups, the ultrastructure showed condensed chromatin arranged along the nuclear membranes, thickened nuclear membranes, and uneven electronic density of the nucleus and cytoplasm (**[Figure 2B](#F2){ref-type="fig"}**). 2-BFI treatment reduced the numbers of condensed chromatins and alleviated thickened nuclear membrane at all time points. Good protection was observed in groups that received 2-BFI within 7 hours after reperfusion (**[Figure 2B](#F2){ref-type="fig"}**).

To determine the DNA injury of the neurons in penumbra area after focal brain ischemia/reperfusion, TUNEL staining was performed in paraffin sections (Han et al., 2010). A few apoptotic neurons were observed in sham-operated rats, while markedly increased apoptotic neurons were found in the penumbra area of both MCAO rats and all 2-BFI treated rats (**[Figure 3](#F3){ref-type="fig"}**). However, 2-BFI used within 5 hours after reperfusion remarkably reduced the number of TUNEL-positive cells compared with the MCAO group (all *P* \< 0.01; **[Figure 3B](#F3){ref-type="fig"}**). The protective effects could still be detected when 2-BFI was administered at 7 and 9 hours after reperfusion (all *P* \< 0.05; **[Figure 3B](#F3){ref-type="fig"}**).

![Effects of 2-BFI on apoptosis in cerebral ischemia/reperfusion rats.\
Rats were subjected to 2-hour MCAO followed by reperfusion. At 0, 1, 3, 5, 7, or 9 hours after reperfusion, 2-BFI (3 mg/kg) was injected intravenously and rats were killed at 22 hours of reperfusion. (A) Frozen rat brains were sectioned and fixed for TUNEL as described in the Methods. Arrowheads indicate TUNEL-positive cells on the ischemic side of the brain. These cells were counted in randomly selected fields under a 40× objective. The number of TUNEL-positive cells (brown) was obviously higher than in sham-treated rats, and 2-BFI reversed this increase in a time-dependent manner. Scale bar: 10 μm. (B) Quantitative analysis of the number of TUNEL-positive cells/40-fold field. The number was markedly smaller in 2-BFI-treated rats than in control rats, particularly in rats that received 2-BFI within 5 hours after injury. Data are expressed as the mean ± SE (*n* = 6 per group; paired *t*-test). \**P* \< 0.05, \*\**P* \< 0.01, *vs*. MCAO group. 2-BFI: 2-(2-Benzofu-ranyl)-2-imidazoline; MCAO: middle cerebral artery occlusion; TUNEL: terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling; h: hour(s).](NRR-13-2111-g004){#F3}

2-BFI treatment up-regulates Bcl-2 expression and down-regulates BAX expression in the ischemic brain of cerebral ischemia/reperfusion rats {#sec2-12}
-------------------------------------------------------------------------------------------------------------------------------------------

In the sham-operated rats, few Bcl-2- and BAX-positive cells were detected. More Bcl-2- and BAX-positive cells were observed in the MCAO and 2-BFI treatment groups (Figure **[4A](#F4){ref-type="fig"}** and **[B](#F4){ref-type="fig"}**). Moderated Bcl-2-positive cells were found in the peri-ischemic brain tissue in the MCAO group and rats treated with 2-BFI after 5 hours. However, the number of Bcl-2-positive cells in rats treated with 2-BFI was significantly higher than in the MCAO group when the compound was given within 5 hours after reperfusion, but similar to the MCAO group when the compound was given at 7 hours or later (all *P* \> 0.05; **[Figure 4C](#F4){ref-type="fig"}**). Similar numbers of Bcl-2-positive cells were observed when 2-BFI was administered at 0 or 1 hour after reperfusion.

![Modulation of apoptosis-related proteins by 2-BFI in cerebral ischemia/reperfusion rats.\
Rats were subjected to 2 hours MCAO followed by reperfusion. At 0, 1, 3, 5, 7, or 9 hours after reperfusion, 2-BFI (3 mg/kg) was injected intravenously and rats were killed at 22 hours after reperfusion. (A) Representative micrographs of tissue immunostained against Bcl-2 (white arrowheads indicate Bcl-2-positive neurons in the ischemic penumbra). (B) Representative micrographs of tissue immunostained against BAX (white arrowheads indicate BAX-positive neurons in the ischemic penumbra). Scale bars: 10 μm. (C) Numbers of Bcl-2-positive neurons in randomly selected fields of brain slices under a 40× objective. The number of positive neurons was higher in the MCAO rats than in sham-operated rats (*n* = 5 for each group). (D) Numbers of BAX-positive cells in randomly selected fields of brain slices under a 40× objective. The number of positive neurons was higher in the MCAO rats than in sham-operated rats. Data are expressed as the mean ± SE (*n* = 6 per group; paired *t*-test). \**P* \< 0.05, *vs*. MCAO group. 2-BFI: 2-(2-Benzofu-ranyl)-2-imidazoline; MCAO: middle cerebral artery occlusion; h: hour(s).](NRR-13-2111-g005){#F4}

The opposite results were observed in BAX-positive cells. The MCAO group showed a remarkable increase of BAX-positive cells in the peri-ischemic brain tissue. Of the rats subjected to occlusion, rats treated with 2-BFI within 5 hours showed significantly fewer BAX-positive cells than the MCAO group (all *P* \< 0.05). The rats treated with 2-BFI at 7 and 9 hours also showed a lower number of BAX-positive cells, but this difference was not significant (**[Figure 4D](#F4){ref-type="fig"}**).

Discussion {#sec1-4}
==========

Research on neuroprotective compounds that target NMDAR has been a high research priority for decades. The greatest challenge is to selectively block NMDAR-mediated neuronal toxicity while reserving the normal physiological functions of the glutamate receptor. Memantine, a noncompetitive NMDAR antagonist, is widely used in the clinic (Vogels et al., 1997; Lipton, 2006). The I~2~R ligand 2-BFI reversibly blocks NMDAR in a way similar to memantine (Jiang et al., 2010; Han et al., 2013), thereby protecting the brain from ischemic insult (Gustafson et al., 1990; Maiese et al., 1992; Han et al., 2009). Previous studies have focused only on the neuroprotective effects of 2-BFI administered immediately after ischemia onset, which is rarely feasible in clinical settings (Gustafson et al., 1990; Maiese et al., 1992; Han et al., 2009). To successfully translate 2-BFI from the laboratory to the clinic, it is necessary to determine whether the drug is effective when given with a certain delay after stroke onset. The findings of our study support our hypothesis that 2-BFI can effectively protect neurons from ischemic injury when administered within 5 hours after reperfusion. Under these conditions, the drug was associated with better neurological motor function, greater reduction in infarct volume, and less apoptosis at 22 hours after reperfusion compared with the MCAO group. However, initiating 2-BFI treatment after 5 hours conferred very limited protection. Further studies showed that the observed anti-apoptotic effect of 2-BFI is strongly related to the down-regulation of pro-apoptotic BAX and up-regulation of anti-apoptotic Bcl-2 expression.

In the intraluminal rat model of MCAO, ischemia triggers hypoxic injury and necrosis, which leads to varying degrees of neurological deficit in the contralateral limb. Brain injury is then exacerbated by reperfusion which involves complex pathophysiological processes, including apoptosis, necrosis, and ischemia surrounding the ischemic core area, as well as complex changes in gene expression (Friedlander, 2003). The present study shows that 2-BFI can remarkably improve neurological performance of rats and reduce infarct volume. Our findings are in accordance with previous findings that 2-BFI and another I~2~R ligand, idazoxan, can reduce infarct volume, improve neurological deficits, and decrease the volume of cell death in the penumbra after transient focal cerebral ischemia (Maiese et al., 1992; Han et al., 2009, 2012). To our knowledge, this is the first study to elucidate the effective therapeutic time window of 2-BFI for ischemic injury. Our findings suggest that drug administration with a certain delay can still provide neuroprotection against ischemic stroke, which increases its potential for clinical use, where delays are common. Although preclinical studies have examined at least 1026 neuroprotective strategies, none have resulted in approved stroke treatments (Sutherland et al., 2012). One important reason for this failure is the lack of a clear therapeutic time window for neuroprotectants. In our study, 2-BFI used within 5 hours after reperfusion reduced neurological deficit and infarct volume in a time-dependent manner, whereby the earlier the administration of 2-BFI, the greater the protection. Nevertheless, we were still able to detect some protective effects even at 9 hours after reperfusion. This demonstrates the importance of starting 2-BFI treatment during the latent phase of recovery, before secondary deterioration with seizures and cytotoxic edema.

Our TUNEL staining results revealed that 2-BFI mitigates apoptosis after ischemia. Not only did 2-BFI remarkably decreased the numbers of apoptotic cells in the penumbra area, but levels of apoptosis also increased rapidly with longer delays. This finding is in accordance with the fact that neuroprotection therapies exert better effect when administrated earlier after stroke by earlier interrupting the cascade of biochemical events after ischemia. Although a single neuroprotective agent may not be enough to provide remarkable protection alone, the time window of 2-BFI efficacy means that it could potentially be combined with other protective treatments, such as thrombolysis, to protect the brain from ischemic insult.

Our previous study found that 2-BFI is a non-competitive inhibitor of NMDAR with a fast-off rate, and that, during excitotoxicity, it reduces intracellular overload of Ca^2+^ in neurons, which is mediated by NMDAR (Han et al., 2013). Excessive intracellular Ca^2+^ triggers intrinsic stimulated apoptosis through the mitochondrial signaling pathway (Liu et al., 2016). It is unclear when cell death becomes irreversible in the ischemic process. Apoptosis, a basic characteristic of all rat cells, is necessary for normal development and tissue homeostasis (Nagata, 1997; Henson and Hume, 2006). Two main pathways, the intrinsic and extrinsic pathways, contribute to post-ischemia apoptosis. The intrinsic pathway is thought to be triggered intracellularly by mitochondria dysfunction (Green and Reed, 1998), whereas the extrinsic pathway is induced through receptors on cell surfaces (Ashkenazi and Dixit, 1998). We hypothesize that 2-BFI may protect the brain by suppressing Ca^2+^ influx, thereby reducing the triggering of the intrinsic (mitochondrial) pathway of apoptosis. Simultaneously, 2-BFI may inhibit apoptosis by binding to I~2~R on the outer membrane of mitochondria (Regunathan et al., 1993), thereby inhibiting mitochondrial nitric oxide synthase and cytochrome c oxidase, which in turn alters energy production (Sastre et al., 1996). This pathway is similar to the intrinsic apoptotic pathway that leads to caspase activation and ultimately apoptosis.

While decreasing neurological deficit and infarct volume, 2-BFI also dramatically up-regulated Bcl-2 expression, which is consistent with our previous study (Han et al., 2010). In the present study, this up-regulation was seen even when 2-BFI was administered at 5 hours after reperfusion. These results suggest that 2-BFI exerts neuroprotective effects not only by transiently and reversibly binding to NMDA receptors, but also by stimulating anti-apoptotic pathways. Bcl-2, located mainly on the outer membrane of mitochondria, regulates the release of cytochrome c, a key component of apoptosis, from mitochondria (Yang et al., 1997; Shimizu et al., 1999). The expression of Bcl-2, which blocks translocation of apoptosis-inducing factor from the mitochondria to the nucleus, has been found to increase neuronal survival after focal brain infarction (Zhao et al., 2004; Hu et al., 2017). Our previous study also found that overexpression of Bcl-2 prevents hippocampal neuron death caused by NMDAR-mediated excitotoxicity (Wong et al., 2005) and that its expression can inhibit apoptosis of newborn neurons and reduce infarct volume after MCAO (Martinou et al., 1994; Zhang et al., 2006). In this study, Bcl-2 expression was up-regulated when 2-BFI was used within 5 hours after reperfusion, which was associated with better neurological outcomes, a smaller infarct volume, and reduced apoptosis level. These findings strengthen the argument that 2-BFI protects against ischemic damage by inhibiting apoptosis.

Similar to Bcl-2, the pro-apoptotic BAX plays a role in neuronal apoptosis, which is caused by various insults to neurons, including excitotoxicity, oxidative stress, and deprivation of trophic factors (Jin et al., 2016; Sun et al., 2017). BAX functions together with the Bcl-2 antagonist/killer (BAK) protein to trigger mitochondrial dysfunction, which is strongly associated with apoptosis (Wei et al., 2001). The balance between pro-apoptotic factors (*e.g*. BAK and BAX) and anti-apoptotic factors (*e.g* Bcl-2 and Bcl-XL) in the BCL-2 superfamily is finely regulated by the intrinsic apoptotic pathway. Our results revealed an inverse trend of Bcl-2 and BAX change with the delay of 2-BFI use, which is similar to the report that higher ratios of Bcl-2 to BAX promote neuronal survival after ischemia (Sulejczak et al., 2004). Our study is the first to report that 2-BFI affects BAX expression after ischemia, and that it simultaneously increases Bcl-2 and decreases BAX expression. The effects of 2-BFI on BAX expression were greatest when the compound was given within 3 hours after stroke, although effects were still measurable up to 5 hours after reperfusion.

Our study has some limitations. First, our animal model is a reperfusion model and 2-BFI may exert neuroprotection based on reperfusion. It is unclear if 2-BFI would have a similar effect on a brain without reperfusion. Our next step is to investigate the effect of 2-BFI on permanent ischemia. Second, the protection was observed at 24 hours after reperfusion and the long-term protective effect is still unclear. In clinical practice, long-term protection may be associated with the outcome of stroke. Further studies should investigate the effects of 2-BFI on the long-term recovery of stroke.

In conclusion, we proposed that 2-BFI exerts strong neuroprotective effects when administered up to 5 hours after reperfusion, and even stronger effects when given within 3 hours. Our study provided the optimal time window of 2-BFI use after infarction. Because of the time window, 2-BFI treatment could be potentially used in clinical practice. Further studies may investigate combination of 2-BFI with recanalization or other neuroprotective strategies.
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